Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 534 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: external beam radiation therapy Clear all
Completed Phase 2 Interventional

Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

NCT00096070
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
radiation therapy, oxaliplatin, fluorouracil, gemcitabine hydrochloride
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 4, 2026, 7:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma

NCT03566199
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
Panobinostat Nanoparticle Formulation MTX110, Convection-Enhanced Delivery (CED)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 4, 2026, 7:32 PM EDT
Completed Not applicable Interventional

Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma

NCT03612648
View directory record Official record
Conditions
Breast Carcinoma, Breast Cancer
Interventions
Three Fraction Accelerated Partial Breast Irradiation, Partial mastectomy
Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 4, 2026, 7:32 PM EDT
Completed Not applicable Interventional Results available

Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00499447
View directory record Official record
Conditions
Lung Cancer
Interventions
radiofrequency ablation, radiation therapy
Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 4, 2026, 7:32 PM EDT
Completed No phase listed Observational

Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

NCT03535987
View directory record Official record
Conditions
Prostate Cancer
Interventions
myocardial PET imaging
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
51 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 4, 2026, 7:32 PM EDT
Terminated Not applicable Interventional Results available

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

NCT01367301
View directory record Official record
Conditions
Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Carcinosarcoma
Interventions
paclitaxel, carboplatin, external beam radiation therapy, brachytherapy, intensity-modulated radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 4, 2026, 7:32 PM EDT
Completed Not applicable Interventional

Prehabilitation for Pelvic Cancer: Changes in Setup Variability

NCT03242538
View directory record Official record
Conditions
Pelvic Cancer
Interventions
Pelvic Exercise
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 4, 2026, 7:32 PM EDT
Terminated Phase 1 Interventional Results available

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

NCT03345784
View directory record Official record
Conditions
Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Stage I Uterine Corpus Cancer AJCC v7, Stage I Vaginal Cancer AJCC v6 and v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Vaginal Carcinoma
Interventions
Adavosertib, Cisplatin, External Beam Radiation Therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Sacramento, California • Aurora, Colorado • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 4, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

NCT01096368
View directory record Official record
Conditions
Anaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma, Clear Cell Ependymoma, Ependymoma, Papillary Ependymoma
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Cisplatin, Clinical Observation, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Mesna, Vincristine
Radiation · Drug · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
181
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 4, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

NCT00116142
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Androgen Hormonal Suppression and Radiation, Androgen Suppression Therapy and Radiation Therapy
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
30 Years and older · Male only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 4, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

NCT02625610
View directory record Official record
Conditions
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Interventions
Avelumab, Oxaliplatin, 5-Fluorouracil, Leucovorin, Capecitabine, Best supportive care
Drug · Other
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
35
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 4, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

NCT00313560
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 4, 2026, 7:32 PM EDT
Recruiting Not applicable Interventional

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

NCT05313191
View directory record Official record
Conditions
CNS Cancer, Head and Neck Cancer, GI Cancer, Gynecologic Cancer, Prostate Cancer, Thoracic Cancer, Breast Cancer
Interventions
Pencil Beam Scanning Proton Therapy
Radiation
Lead sponsor
The New York Proton Center
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 4, 2026, 7:32 PM EDT
Completed Phase 1 Interventional

Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment

NCT00061347
View directory record Official record
Conditions
Prostate Cancer, Cancer
Interventions
Fiducial marker placement
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 4, 2026, 7:32 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial

NCT01558921
View directory record Official record
Conditions
Rectal Cancer
Interventions
M1 scheme, standard long course chemoradiotherapy
Other
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 4, 2026, 7:32 PM EDT
Terminated Phase 2 Interventional Results available

Nuvigil or Placebo in Newly Diagnosed Malignant Glioma

NCT01400958
View directory record Official record
Conditions
Malignant Glioma
Interventions
Nuvigil®, Placebo
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 4, 2026, 7:32 PM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

NCT01644591
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 4, 2026, 7:32 PM EDT
Recruiting Not applicable Interventional

High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis

NCT05301101
View directory record Official record
Conditions
Solid Tumor
Interventions
Re-irradiation
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 4, 2026, 7:32 PM EDT
Withdrawn Not applicable Interventional

Stereotactic Radiation Therapy Before Surgery for the Treatment of Resectable Brain Metastases

NCT04069910
View directory record Official record
Conditions
Malignant Neoplasm, Brain, Brain Tumor
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Therapeutic Conventional Surgery
Other · Radiation · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 4, 2026, 7:32 PM EDT
Completed Phase 2 Interventional

Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer

NCT00003124
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, leuprolide acetate, radiation therapy
Drug · Radiation
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 4, 2026, 7:32 PM EDT
Recruiting Phase 2 Interventional

5-Day Preoperative Radiation for Soft Tissue Sarcoma

NCT06087861
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
External Beam Radiotherapy
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 4, 2026, 7:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

NCT04599062
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Talimogene Laherparepvec, Radiotherapy
Drug · Radiation
Lead sponsor
John Rieth
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 4, 2026, 7:32 PM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT01899261
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 4, 2026, 7:32 PM EDT
Terminated Not applicable Interventional Results available

Magnetic Resonance Imaging-Based Radiation Therapy and Cisplatin in Patients With Stage I, Stage II, Stage III, or Stage IV Cervical Cancer

NCT01016561
View directory record Official record
Conditions
Cervical Cancer
Interventions
intracavitary balloon brachytherapy, external beam radiation therapy, intensity-modulated radiation therapy, radiation therapy treatment planning/simulation, 3-dimensional conformal radiation therapy, Cisplatin
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 4, 2026, 7:32 PM EDT